JPS6259092B2 - - Google Patents

Info

Publication number: JPS6259092B2
Authority: JP; Japan
Prior art keywords: platelet aggregation; prp; substance; adp; effect
Prior art date: 1983-06-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

JP11942883A

Other languages

English (en)

Japanese (ja)

Other versions

JPS6011420A (ja

Inventor

Hideyuki Yamato

Juji Maeda

Fumiaki Yoshino

Atsuya Takahata

Masanori Ubusawa

Tadaaki Kato

Chikao Yoshikumi

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Kureha Corp

Original Assignee

Kureha Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-06-30

Filing date

1983-06-30

Publication date

1987-12-09

1983-06-30 Application filed by Kureha Corp filed Critical Kureha Corp

1983-06-30 Priority to JP11942883A priority Critical patent/JPS6011420A/ja

1984-06-15 Priority to US06/620,923 priority patent/US4501738A/en

1984-06-27 Priority to IT21627/84A priority patent/IT1176336B/it

1984-06-28 Priority to BE0/213228A priority patent/BE900026A/fr

1984-10-01 Priority to US06/656,760 priority patent/US4534975A/en

1985-01-21 Publication of JPS6011420A publication Critical patent/JPS6011420A/ja

1987-12-09 Publication of JPS6259092B2 publication Critical patent/JPS6259092B2/ja

Status Granted legal-status Critical Current

Links

229940127218 antiplatelet drug Drugs 0.000 claims description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
FCKJYANJHNLEEP-SRLFHJKTSA-N 24,25-dihydroxycholecalciferol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCC(O)C(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C FCKJYANJHNLEEP-SRLFHJKTSA-N 0.000 claims description 5
201000010099 disease Diseases 0.000 claims description 5
239000004480 active ingredient Substances 0.000 claims description 4
230000002785 anti-thrombosis Effects 0.000 claims description 3
239000003146 anticoagulant agent Substances 0.000 claims description 3
FCKJYANJHNLEEP-XRWYNYHCSA-N (24R)-24,25-dihydroxycalciol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CC[C@@H](O)C(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C FCKJYANJHNLEEP-XRWYNYHCSA-N 0.000 claims 1
239000004046 24R,25-dihydroxy-cholecalciferol Substances 0.000 claims 1
239000003795 chemical substances by application Substances 0.000 claims 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 35
239000000126 substance Substances 0.000 description 18
208000010110 spontaneous platelet aggregation Diseases 0.000 description 16
230000000694 effects Effects 0.000 description 13
241000700159 Rattus Species 0.000 description 12
210000004369 blood Anatomy 0.000 description 9
239000008280 blood Substances 0.000 description 9
210000001772 blood platelet Anatomy 0.000 description 9
206010050661 Platelet aggregation inhibition Diseases 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
238000005259 measurement Methods 0.000 description 4
239000000203 mixture Substances 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
239000000243 solution Substances 0.000 description 4
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 4
206010020772 Hypertension Diseases 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
206010012601 diabetes mellitus Diseases 0.000 description 3
235000014113 dietary fatty acids Nutrition 0.000 description 3
239000000194 fatty acid Substances 0.000 description 3
229930195729 fatty acid Natural products 0.000 description 3
150000004665 fatty acids Chemical class 0.000 description 3
238000009472 formulation Methods 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
-1 triglyceride ester Chemical class 0.000 description 3
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
230000007059 acute toxicity Effects 0.000 description 2
231100000403 acute toxicity Toxicity 0.000 description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
230000001162 anti-hypercalcemic effect Effects 0.000 description 2
238000013176 antiplatelet therapy Methods 0.000 description 2
239000002775 capsule Substances 0.000 description 2
208000026106 cerebrovascular disease Diseases 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
238000011160 research Methods 0.000 description 2
239000007901 soft capsule Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
241000251468 Actinopterygii Species 0.000 description 1
239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
208000011200 Kawasaki disease Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
206010029164 Nephrotic syndrome Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
208000003782 Raynaud disease Diseases 0.000 description 1
208000012322 Raynaud phenomenon Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
244000299461 Theobroma cacao Species 0.000 description 1
235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
208000005485 Thrombocytosis Diseases 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 1
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
208000032109 Transient ischaemic attack Diseases 0.000 description 1
GSNOZLZNQMLSKJ-UHFFFAOYSA-N Trapidil Chemical compound CCN(CC)C1=CC(C)=NC2=NC=NN12 GSNOZLZNQMLSKJ-UHFFFAOYSA-N 0.000 description 1
229930003316 Vitamin D Natural products 0.000 description 1
QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
230000001565 angiopathic effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
230000000767 anti-ulcer Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000006502 antiplatelets effects Effects 0.000 description 1
229960004676 antithrombotic agent Drugs 0.000 description 1
210000000702 aorta abdominal Anatomy 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
239000002473 artificial blood Substances 0.000 description 1
239000012237 artificial material Substances 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
238000010876 biochemical test Methods 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
230000005587 bubbling Effects 0.000 description 1
235000001046 cacaotero Nutrition 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
206010008118 cerebral infarction Diseases 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000001177 diphosphate Substances 0.000 description 1
XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
235000011180 diphosphates Nutrition 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
235000006694 eating habits Nutrition 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
230000029142 excretion Effects 0.000 description 1
235000019688 fish Nutrition 0.000 description 1
238000003304 gavage Methods 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
208000007475 hemolytic anemia Diseases 0.000 description 1
201000005991 hyperphosphatemia Diseases 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
230000036737 immune function Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000008101 lactose Substances 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
229910052753 mercury Inorganic materials 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
238000013059 nephrectomy Methods 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
150000002978 peroxides Chemical class 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
210000004623 platelet-rich plasma Anatomy 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
201000011461 pre-eclampsia Diseases 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
238000003307 slaughter Methods 0.000 description 1
239000007787 solid Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
WSWCOQWTEOXDQX-MQQKCMAXSA-N sorbic acid group Chemical class C(\C=C\C=C\C)(=O)O WSWCOQWTEOXDQX-MQQKCMAXSA-N 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
229960001052 streptozocin Drugs 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
229960005001 ticlopidine Drugs 0.000 description 1
235000010215 titanium dioxide Nutrition 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
201000010875 transient cerebral ischemia Diseases 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
229960000363 trapidil Drugs 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
235000019166 vitamin D Nutrition 0.000 description 1
239000011710 vitamin D Substances 0.000 description 1
150000003710 vitamin D derivatives Chemical class 0.000 description 1
QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical class C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
229940046008 vitamin d Drugs 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

JP11942883A 1983-06-30 1983-06-30 抗血小板剤 Granted JPS6011420A (ja)

Priority Applications (5)

Application Number	Priority Date	Filing Date	Title
JP11942883A JPS6011420A (ja)	1983-06-30	1983-06-30	抗血小板剤
US06/620,923 US4501738A (en)	1983-06-30	1984-06-15	Pharmaceutical composition containing 24,25-dihydroxycholecalciferol as an active ingredient to treat pain, pyrexia or inflammatory diseases
IT21627/84A IT1176336B (it)	1983-06-30	1984-06-27	Composizione farmaceutica contenente come ingrediente attivo 24,25-diidrossicolecalciferolo
BE0/213228A BE900026A (fr)	1983-06-30	1984-06-28	Composition pharmaceutique contenant du 24,25-dihydroxy-cholecalciferol.
US06/656,760 US4534975A (en)	1983-06-30	1984-10-01	Pharmaceutical composition containing 24,25-dihydroxycholecalciferol in methods of treatment

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP11942883A JPS6011420A (ja)	1983-06-30	1983-06-30	抗血小板剤

Publications (2)

Publication Number	Publication Date
JPS6011420A JPS6011420A (ja)	1985-01-21
JPS6259092B2 true JPS6259092B2 (fr)	1987-12-09

Family

ID=14761192

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP11942883A Granted JPS6011420A (ja)	1983-06-30	1983-06-30	抗血小板剤

Country Status (1)

Country	Link
JP (1)	JPS6011420A (fr)

1983
- 1983-06-30 JP JP11942883A patent/JPS6011420A/ja active Granted

Also Published As

Publication number	Publication date
JPS6011420A (ja)	1985-01-21

Publication	Publication Date	Title
DE69607750T2 (de)	2000-08-31	Aminosäurenzusammensetzungen und verwendung derselben klinischen nährung
ES2235205T3 (es)	2005-07-01	Capsula que contiene compuestos de dioxabiciclo (3.3.0)octano.
JP2000219624A (ja)	2000-08-08	インスリン抵抗性糖尿病のための食事用補添物
EP0336851A1 (fr)	1989-10-11	Composition pharmaceutique pour administration orale à base d'un dérivé d'acide diphosphonique
US10905657B2 (en)	2021-02-02	Solid dispersions of Coenzyme Q10
GB1580444A (en)	1980-12-03	Pharmaceutical compositions
EP0759294B1 (fr)	2002-04-17	Agent thérapeutique pour le traitement de l'hypercholestérolémie
Bustos et al.	1970	Pyrazole and induction of fatty liver by a single dose of ethanol
JP3075358B2 (ja)	2000-08-14	肝機能改善剤
Stout	1971	The effect of insulin on the incorporation of sodium (1-14C)-acetate into the lipids of the rat aorta
PT2097080E (pt)	2013-04-01	Utilização de um ácido indazolmetoxialcanóico para a redução dos níveis de triglicéridos, colesterol e glucose
WO2002047682A1 (fr)	2002-06-20	Composition ameliorant les lipides sanguins
US4534975A (en)	1985-08-13	Pharmaceutical composition containing 24,25-dihydroxycholecalciferol in methods of treatment
US20170246136A1 (en)	2017-08-31	Pharmaceutical product, medical food or dietary supplement for preventing cancer and inflammatory diseases
Di Luzio	1962	Comparative study of the effect of alcoholic beverages on the development of the acute ethanol-induced fatty liver
JPS6259092B2 (fr)	1987-12-09
EP0114577A1 (fr)	1984-08-01	Composition pharmaceutique
WO1992012706A1 (fr)	1992-08-06	Procede permettant de reduire des taux eleves de glycemie chez l'homme
JP2006516568A (ja)	2006-07-06	加齢関連性障害を処置するための組成物および方法
JP3029902B2 (ja)	2000-04-10	血清脂質増加剤
JP2746079B2 (ja)	1998-04-28	血糖上昇抑制剤および脂質代謝改善剤
EP3197439B1 (fr)	2019-12-04	Produit pharmaceutique, aliment médical ou supplément diététique pour la prévention du cancer et de maladies inflammatoires
JPS6221330B2 (fr)	1987-05-12
JPS5843385B2 (ja)	1983-09-27	シジミの薬効成分及びその製造法
JPS6221333B2 (fr)	1987-05-12